{"id":"https://openalex.org/W2569954893","doi":"https://doi.org/10.1182/blood.v108.11.660.660","title":"CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.","display_name":"CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.","publication_year":2006,"publication_date":"2006-11-16","ids":{"openalex":"https://openalex.org/W2569954893","doi":"https://doi.org/10.1182/blood.v108.11.660.660","mag":"2569954893"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v108.11.660.660","doi":"https://doi.org/10.1182/blood.v108.11.660.660","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.660.660","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025602290","display_name":"Susann M. Szmania","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susann Szmania","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078553844","display_name":"Balaji Balasa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Balaji Balasa","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048455792","display_name":"Priyangi A. Malaviarachchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152047","display_name":"PDL BioPharma (United States)","ror":"https://ror.org/03ya6pd97","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152047"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Priyangi Malaviarachchi","raw_affiliation_strings":["Department of Research, PDL BioPharma, Fremont, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research, PDL BioPharma, Fremont, CA, USA","institution_ids":["https://openalex.org/I4210152047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015879466","display_name":"Fenguhuang Zhan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fenguhuang Zhan","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026993384","display_name":"Yongsheng Huang","orcid":"https://orcid.org/0000-0002-6114-7730","observed_orcids":["https://orcid.org/0000-0002-6114-7730"]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yongsheng Huang","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006837673","display_name":"Aparna Draksharapu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aparna Draksharapu","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086538195","display_name":"Vladimir S. Vexler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152047","display_name":"PDL BioPharma (United States)","ror":"https://ror.org/03ya6pd97","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152047"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vladimir Vexler","raw_affiliation_strings":["Department of Research, PDL BioPharma, Fremont, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research, PDL BioPharma, Fremont, CA, USA","institution_ids":["https://openalex.org/I4210152047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027806317","display_name":"John D. Shaughnessy","orcid":"https://orcid.org/0000-0002-2017-6236","observed_orcids":["https://orcid.org/0000-0002-2017-6236"]},"institutions":[{"id":"https://openalex.org/I4210152047","display_name":"PDL BioPharma (United States)","ror":"https://ror.org/03ya6pd97","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152047"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Shaughnessy","raw_affiliation_strings":["Department of Research, PDL BioPharma, Fremont, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research, PDL BioPharma, Fremont, CA, USA","institution_ids":["https://openalex.org/I4210152047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000879635","display_name":"Bart Barlogie","orcid":"https://orcid.org/0000-0001-6116-1017","observed_orcids":["https://orcid.org/0000-0001-6116-1017"]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bart Barlogie","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007261675","display_name":"Guido J. K. Tricot","orcid":"https://orcid.org/0000-0002-3111-9739","observed_orcids":["https://orcid.org/0000-0002-3111-9739"]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guido Tricot","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110642033","display_name":"Daniel Afar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Afar","raw_affiliation_strings":["Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002688233","display_name":"van Rhee Frits","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152047","display_name":"PDL BioPharma (United States)","ror":"https://ror.org/03ya6pd97","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152047"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"van Rhee Frits","raw_affiliation_strings":["Department of Research, PDL BioPharma, Fremont, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research, PDL BioPharma, Fremont, CA, USA","institution_ids":["https://openalex.org/I4210152047"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.3866,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.68657624,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"108","issue":"11","first_page":"660","last_page":"660"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.7770000100135803},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.7580000162124634},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9290000200271606},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.7490000128746033},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.765999972820282},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.8610000014305115},{"id":"https://openalex.org/keywords/fc-receptors","display_name":"Fc receptors","score":0.6340000033378601},{"id":"https://openalex.org/keywords/autologous-nk-cells","display_name":"autologous NK cells","score":0.7850000262260437},{"id":"https://openalex.org/keywords/plasma-cells","display_name":"plasma cells","score":0.4440000057220459}],"concepts":[{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7265909910202026},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5767195820808411},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.5758123397827148},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.513981282711029},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.49702075123786926},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4963300824165344},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4703395962715149},{"id":"https://openalex.org/C2776396001","wikidata":"https://www.wikidata.org/wiki/Q250694","display_name":"Plasma cell","level":3,"score":0.46115732192993164},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.4152508080005646},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.40189021825790405},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3635888695716858},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33979254961013794},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33216339349746704}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v108.11.660.660","doi":"https://doi.org/10.1182/blood.v108.11.660.660","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.660.660","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2587702152","https://openalex.org/W2128644254","https://openalex.org/W2532706264","https://openalex.org/W2547936883","https://openalex.org/W2004543856","https://openalex.org/W2580070551","https://openalex.org/W4389248119","https://openalex.org/W2558586991","https://openalex.org/W2914197989","https://openalex.org/W1969110349"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"One-third":[2],"of":[3,18,23,36,47,88,92,143,163,170,210,231,251,274,292,305,321,335,381,395],"multiple":[4],"myeloma":[5,77,101,144,175,181,221,252,275,308,322,349,382,396],"(MM)":[6],"patients":[7,189,211],"exhibit":[8],"high-risk":[9],"features":[10],"such":[11,48],"as":[12],"abnormal":[13],"cytogenetics,":[14],"high":[15,202,300],"LDH,":[16],"amplification":[17],"CKS1-B":[19],"or":[20,26],"spiked":[21],"expression":[22,98,116,125,199,214,218,304],"MAF,":[24],"MAF-B":[25],"FGFR3.":[27],"While":[28],"not":[29,51],"affecting":[30],"complete":[31],"response":[32],"rates,":[33],"median":[34],"durations":[35],"event-free":[37],"and":[38,55,62,131,177,302,314,317],"overall":[39],"survival,":[40],"even":[41],"with":[42,179,207,326],"high-dose":[43],"melphalan-based":[44],"tandem":[45],"autotransplants":[46],"patients,":[49,176,316],"do":[50],"exceed":[52],"24":[53],"mo":[54,61,65],"36":[56],"mo,":[57],"compared":[58],"to":[59],"60":[60],"\u2265":[63],"90":[64],"for":[66,110,347],"the":[67,89,262,331],"remainder.":[68],"Monoclonal":[69],"antibody":[70,147,378,392],"(mAb)-mediated":[71],"therapy":[72],"may":[73],"target":[74,109],"a":[75,86,107,136,195,208,342],"chemotherapy-resistant":[76],"cell":[78,93,290],"pool.":[79],"CS1":[80,105,157,184,198,216,306,353,365,377,391],"(CD2":[81],"subset":[82,209],"1,":[83],"CRACC,":[84],"SLAMF7),":[85],"member":[87],"CD2":[90],"family":[91],"surface":[94],"glycoproteins,":[95],"exhibits":[96],"high-level":[97],"on":[99,219,238],"primary":[100,220],"cells,":[102],"indicating":[103,269],"that":[104,246,284],"is":[106,355,367],"potential":[108,332],"treatment":[111],"in":[112,161,188,280,307,324,358,370],"MM.":[113],"Methods:":[114],"Gene":[115],"was":[117,126,152,159,200,223,277],"assessed":[118],"using":[119,134,254],"an":[120,270],"Affymetrix":[121],"GeneChip":[122],"array.":[123],"Protein":[124],"measured":[127,153],"by":[128,154,225,384,398],"flow":[129,226],"cytometry,":[130,227],"immunohistochemistry":[132],"(IHC),":[133],"HuLuc63,":[135],"novel":[137],"humanized":[138],"anti-CS1":[139,235],"mAb.":[140],"HuLuc63-mediated":[141],"lysis":[142,320],"cells":[145,167,222,253,258,323,383,397],"via":[146],"dependent":[148],"cellular":[149],"cytotoxicity":[150],"(ADCC)":[151],"51Cr-release.":[155],"Results:":[156],"mRNA":[158,301,354,366],"detected":[160],">95%":[162,169],"CD138+":[164,239,359,371],"purified":[165,255,360,372],"plasma":[166,241],"from":[168,309],"healthy":[171],"donors,":[172],"newly":[173],"diagnosed":[174],"those":[178],"relapsed":[180],"(Fig.":[182,259],"1a).":[183],"remained":[185],"highly":[186,356,368],"expressed":[187,357,369],"following":[190,203],"VDTPACE":[191],"treatment,":[192,206],"albeit":[193],"at":[194],"reduced":[196,266],"level.":[197],"also":[201,278],"bortezomib":[204],"(Velcade\u00ae)":[205],"showing":[212],"increased":[213],"post-treatment.":[215],"protein":[217,303],"confirmed":[224],"while":[228],"IHC":[229],"analysis":[230],"normal":[232],"tissues":[233],"revealed":[234],"staining":[236],"primarily":[237],"tissue":[240],"cells.":[242,295,362,374,388,402],"Finally,":[243],"we":[244,298],"determined":[245],"HuLuc63":[247,285,338],"could":[248],"induce":[249],"killing":[250,380,394],"allogeneic":[256],"NK":[257,289,294,387,401],"1b).":[260],"Blocking":[261],"Fc":[263],"receptor":[264],"greatly":[265],"this":[267],"activity":[268],"ADCC":[271],"mechanism.":[272],"Killing":[273],"targets":[276],"observed":[279,299],"autologous":[281,293],"systems":[282],"suggesting":[283],"can":[286],"overcome":[287],"KIR-mediated":[288],"inhibition":[291],"In":[296],"summary,":[297],"early":[310],"stage,":[311,313],"late":[312],"treated":[315],"showed":[318],"enhanced":[319],"vitro":[325],"HuLuc63.":[327],"Our":[328],"data":[329],"support":[330],"clinical":[333,345],"utility":[334],"CS1-targeted":[336],"therapy.":[337],"will":[339],"be":[340],"entering":[341],"phase":[343],"I":[344],"trial":[346],"advanced":[348],"patients.":[350],"Figure":[351,363,375,389],"1a.":[352,364],"plasa":[361,373],"1b.":[376,390],"enhances":[379,393],"allo":[385,399],"-":[386,400]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-01-13T00:00:00"}